GLP-1

News

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.

News

Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

News

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.